Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended) A compound of formula (I):

HONH
$$X$$
 R Y Y Y Y

wherein:

X is C_{1-6} alkylene or C_{2-6} alkenylene, each of which is optionally substituted by one or more fluorine atoms;

R is aryl or C_{3-8} cycloalkyl optionally substituted by one or more fluorine atoms;

W is N-or-CZ;

Y is

(a) NR¹R³,

(b) C_{1-4} alkyl substituted by NR^1R^2 or by a 4- to 7-membered N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring

hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R². =O and OH.

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^2 , =O and OH,

Z is H or C_{1-4} alkyl,

or when W is CZ, Y can be H or C_{1-4} alkyl, and Z can be (a) NR^4R^3 .

(b) C_{1-4} alkyl substituted by NR¹R² or by a 4- to 7-membered N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R². =O and OH.

or (c) a 4- to 7-membered saturated or partially or fully unsaturated N-heterocycle attached via the N-atom, which heterocycle optionally contains 1 or 2 further ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from \mathbb{R}^2 , =O and OH,

 R^2 is H,

C₁₋₆ alkyl (optionally substituted by one or more substituents independently selected from OH, C₁₋₄ alkoxy, C(O)_p(C₁₋₄ alkyl, aryl, heteroaryl, or NR¹R³), CONR¹R³-or NR¹R³).

-SO₂(C₁₋₄-alkyl, aryl, heteroaryl or NR¹R³),

C(O)_p(C₁₋₄-alkyl optionally substituted by C₁₋₄-alkoxy or NR¹R³),

Appl., No. 10/731,707 Amdt. Dated November 8, 2006 Reply to Office action of August 21, 2006

C(O)p(C3-7-cycloalkyl),

 $C(O)_p(aryl)_{r}$

C(O)_e(heteroaryl),

CONR¹R³,

 C_{3-7} cycloalkyl optionally substituted by one or more substituents independently selected from OH and C_{1-4} alkoxy,

a 4- to 7-membered saturated or partially or fully unsaturated heterocycle, which heterocycle ring contains up to 3 ring hetero-atoms independently selected from N, O and S, and which heterocycle is optionally substituted by one or more substituents independently selected from R^3 , =O, OH, $SO_2(C_{1-4}$ alkyl) and/or $C(O)_p(C_{1-4}$ alkyl) groups, or aryl,

 R^1 and R^3 are each independently selected from represented by H_1 and [[(]] C_{1-4} alkyl optionally substituted by OH, NR^4R^5 or by C_{1-4} alkoxy[[)]],

 R^4 and R^5 are each independently selected from represented by H and or C_{1-4} alkyl,

p is 1 or 2,

"aryl" is phenyl optionally substituted by one or more substituents independently selected from R^3 , OH, $SO_2(C_{1-4}$ alkyl) and/or $C(O)_p(C_{1-4}$ alkyl) groups,

"heteroaryl" is a 5- to 7-membered aromatic heterocycle with 1, 2 or 3 ring hetero-atoms independently selected from the group consisting of N, O and S, and which ring is optionally substituted by one or more substituents independently selected from the group consisting of R^3 , =O, OH, $SO_2(C_{1-4}$ alkyl) and [[/or]] $C(O)_p(C_{1-4}$ alkyl) groups,

<u>or a and the</u> pharmaceutically acceptable salts, <u>or</u> solvates (including hydrates) and prodrugs thereof.

Claim 2 (currently amended) A compound, salt, <u>or</u> solvate or prodrug according to claim 1 wherein the compound of formula (I) has the following stereochemistry (IA):

HONH
$$X = R$$
 $N = Y$
 $V = W$
 $V = W$
 $V = W$

Claim 3 (cancelled)

Claim 4 (currently amended) A compound, salt, or solvate or prodrug according to claim 1 wherein X is a linear C_{2-6} alkylene moiety optionally substituted by one or more fluorine atoms.

Claim 5 (currently amended) A compound, salt, or solvate or prodrug according to claim 1 wherein R is C_{3-8} cycloalkyl optionally substituted by one or more fluorine atoms.

Claim 6 and 7 (cancelled)

Claim 8 (currently amended) A compound, salt, or solvate or prodrug according to claim 1 wherein X is propylene.

Appl., No. 10/731,707 Amdt. Dated November 8, 2006 Reply to Office action of August 21, 2006

Claim 9 (currently amended) A compound, salt, <u>or</u> solvate or prodrug according to claim 1 wherein R is cyclobutyl, cyclopentyl or cyclohexyl optionally substituted by one or more fluorine atoms.

Claim 10 (currently amended) A compound, salt, or solvate or prodrug according to claim 1 wherein Y is CH_{2} , substituted by NR^4R^2 , or Y is a 6-membered saturated or partially or fully unsaturated N-heterocycle, and which heterocycle is optionally substituted by one or more substituents independently selected from R^2 , =0 and OH.

Claim 11 (currently amended) A compound, salt, <u>or</u> solvate or prodrug according to claim 1 wherein R is cyclohexyl.

Claims 12-15 (cancelled)

Claim 16 (currently amended) A pharmaceutical composition comprising a compound, salt, <u>or</u> solvate or prodrug according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

Claims 17-19 (cancelled)